Core Viewpoint - Since January 20, WuXi Biologics has outperformed its mainland CRO peers and the overall healthcare sector, indicating its relative resilience in the market [1] Group 1: Company Performance - WuXi Biologics has shown better stock performance compared to mainland CRO peers and the overall healthcare sector since January 20 [1] - The company benefits from a more diversified shareholder structure, which helps buffer against geopolitical risks [1] Group 2: Growth Potential - There is an increased visibility for accelerated growth by 2026, suggesting potential performance may exceed current expectations [1] - As peers in the industry failed to meet profit expectations in Q4 2025, capital is flowing back to WuXi Biologics [1] Group 3: Market Position and Valuation - WuXi Biologics remains the preferred stock in the mainland CRO/CDMO sector according to the report [1] - The company's valuation is at a discount compared to global peers, indicating potential for upside [1] - The target price set for WuXi Biologics is HKD 48.5, with a rating of "outperform" [1]
大行评级｜里昂：药明生物增长加速的能见度提升，评级“跑赢大市”